infect
negativesens
rna
virus
associ
broad
spectrum
human
diseas
influenza
respiratori
syncyti
viru
rsv
recogn
widespread
global
pathogen
other
ebola
viru
ebov
lassa
viru
lasv
hemorrhag
fever
viru
cchfv
known
sporad
outbreak
high
epidem
potenti
high
mortal
rate
negativesens
rna
virus
classifi
segment
nonseg
virus
segment
negativesens
rna
virus
subdivid
famili
contain
two
singlestrand
genom
fragment
arenavirida
eg
lasv
three
fragment
order
bunyavir
formerli
famili
bunyavirida
eg
cchfv
multipl
fragment
orthomyxovirida
eg
influenza
exampl
famili
nonseg
negativesens
rna
virus
singlestrand
rna
genom
mononegaviral
includ
filovirida
eg
ebov
paramyxovirida
eg
nipah
viru
niv
pneumovirida
eg
rsv
prevent
treatment
infect
negativesens
rna
virus
remain
challeng
ebola
viru
diseas
evd
outbreak
west
africa
caus
approxim
case
death
sober
remind
unmet
medic
need
intens
research
effort
outbreak
led
discoveri
develop
sever
vaccin
drug
candid
promis
experiment
vaccin
ebov
base
envelop
glycoprotein
antigen
target
monoclon
antibodi
nucleotid
analogu
inhibitor
repres
investig
therapi
zmapp
cocktail
three
monoclon
antibodi
target
ebov
glycoprotein
shown
revers
evd
nonhuman
primat
howev
result
random
clinic
trial
inconclus
like
glycoproteinbas
vaccin
antibodi
cocktail
also
effect
ebolaviru
speci
contrast
sever
nucleotid
analogu
show
antivir
activ
differ
ebolaviru
speci
also
neg
positivesens
rna
virus
favipiravir
nucleosid
precursor
approv
treatment
pandem
influenza
japan
intracellular
phosphoribosyl
yield
triphosph
form
accommod
viral
rnadepend
rna
polymeras
rdrp
figur
experi
recombin
influenza
rdrp
show
ambigu
basepair
cytidin
uridin
lead
lethal
mutagenesi
incorpor
grow
rna
chain
also
caus
moder
inhibit
rna
synthesi
favipiravir
activ
larg
panel
rna
virus
vitro
includ
ebov
clinic
evalu
challeng
result
multicent
nonrandom
trial
larg
inconclus
structur
base
moieti
propos
mechan
action
reminisc
ribavirin
use
decad
treat
infect
hepat
c
viru
hcv
figur
structur
distinct
broadspectrum
antivir
agent
also
activ
ebov
vitro
galidesivir
galidesivir
adenosinelik
compound
nitrogensubstitut
sugar
ring
likewis
requir
intracellular
activ
tp
form
figur
biochem
experi
show
compound
serv
substrat
rdrp
hcv
caus
chain
termin
follow
incorpor
remdesivir
phosphoramid
prodrug
adenosin
analogu
inhibit
ebolavirus
half
maxim
effect
concentr
submicromolar
rang
consider
lower
valu
report
favipiravir
galidesivir
triphosph
form
remdesivir
remdesivirtp
shown
inhibit
rsv
rdrp
surrog
ebov
rdrp
signific
inhibit
seen
human
rna
pol
ii
human
mitochondri
rna
polymeras
hmtrnap
biochem
data
obtain
purifi
recombin
rsv
rdrp
recent
studi
niv
rdrp
point
delay
chain
termin
possibl
mechan
action
delay
chain
termin
refer
inhibit
rna
synthesi
residu
downstream
incorpor
inhibitor
howev
inhibit
result
yet
translat
quantit
term
data
recombin
ebov
rdrp
lack
rsv
niv
ebov
nonseg
virus
share
similar
requir
rna
synthesi
rdrp
activ
rsv
niv
requir
multifunct
l
protein
phosphoprotein
p
protein
l
protein
contain
polymeras
activ
site
p
protein
necessari
form
activ
complex
recent
express
activ
ebov
rdrp
contain
l
protein
complex
viral
protein
function
equival
p
protein
studi
util
ebov
rdrp
complex
studi
mechan
action
remdesivir
demonstr
incorpor
nucleotid
analogu
posit
caus
delay
chain
termin
predominantli
posit
rna
primer
templat
use
studi
purchas
dharmacon
lafayett
co
usa
remdesivirtp
chemic
synthes
gilead
scienc
foster
citi
ca
usa
araatp
purchas
trilink
san
diego
ca
usa
ntp
purchas
ge
healthcar
cranburi
nj
usa
invitrogen
burlington
canada
plasmid
codonoptim
synthet
dna
sequenc
genscript
piscataway
nj
usa
code
human
mitochondri
dnadepend
rna
polymeras
hmtrnap
viral
protein
complex
ebov
l
rsv
l
p
rdrp
use
start
materi
protein
express
insect
cell
invitrogen
burlington
canada
hmtrnap
construct
design
base
work
smidanski
et
al
follow
modif
strep
tag
ad
nterminu
express
protein
employ
multibac
geneva
biotech
indianapoli
usa
system
protein
product
insect
cell
invitrogen
burlington
canada
accord
protocol
provid
dr
garzoni
bieniossek
berger
hmtrnap
viral
protein
complex
purifi
use
strep
histagaffin
chromatographi
respect
accord
manufactur
specif
iba
goettingen
germani
thermo
scientif
rockford
il
usa
respect
ident
purifi
hmtrnap
confirm
mass
spectrometri
ms
analysi
dr
jack
moor
alberta
proteom
mass
spectrometri
edmonton
ab
canada
data
acquisit
quantif
also
done
previous
report
us
account
potenti
batchtobatch
variat
multipl
prepar
ebov
rdrp
use
data
acquisit
studi
amount
ebov
rdrp
use
rna
synthesi
assay
optim
incorpor
gtp
perkinelm
boston
usa
would
reach
maximum
min
amount
rsv
hmtrnap
optim
similar
appar
activ
ebov
rdrp
test
variou
amount
enzym
involv
employ
lowmicromolar
concentr
ntp
substrat
rna
synthesi
reaction
contain
hmtrnap
rna
synthesi
assay
consist
mix
final
concentr
trishcl
ph
mm
rna
primer
rna
templat
gtp
variou
concentr
combin
ntp
ntp
analogu
ebov
rdrp
ice
note
dna
templat
use
reaction
contain
hmtrnap
reaction
mixtur
incub
min
follow
addit
mm
reaction
stop
min
addit
formamideedta
mm
mixtur
incub
min
reaction
sampl
subject
denatur
urea
polyacrylamid
gel
electrophoresi
resolv
product
rna
synthesi
follow
signal
quantif
imagequ
ge
healthcar
bioscienc
uppsala
sweeden
phosphorimag
typhoon
trio
variabl
mode
imag
ge
healthcar
bioscienc
uppsala
sweeden
incorpor
nucleotid
product
fraction
plot
versu
nucleotid
substrat
concentr
fit
equat
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
short
model
primertempl
serv
substrat
ebov
rdrp
viral
rdrp
enzym
figur
system
mimic
random
elong
complex
allow
evalu
nucleotid
analogu
inhibitor
elucid
mechan
action
remdesivir
initi
assess
whether
remdesivirtp
abl
compet
natur
counterpart
atp
figur
extens
primer
monitor
gtp
serv
first
substrat
reaction
next
site
incorpor
refer
allow
bind
atp
inhibitor
remdesivirtp
fulllength
product
format
requir
simultan
presenc
atp
ctp
rna
synthesi
analyz
three
differ
concentr
natur
substrat
atp
ctp
figur
increas
concentr
inhibitor
three
substrat
concentr
yield
chang
product
pattern
becom
evid
posit
particular
templat
allow
atp
remdesivirtp
bind
posit
slower
migrat
band
posit
indic
inhibitor
incorpor
signific
differ
seen
lowest
concentr
atp
figur
left
panel
higher
concentr
atp
promot
synthesi
faster
migrat
product
contain
nucleotid
analogu
figur
middl
right
panel
gradual
chang
demonstr
competit
atp
remdesivirtp
subsequ
rna
product
posit
show
even
complex
shift
consequ
multipl
competit
event
howev
signific
reduct
rna
synthesi
evid
condit
therefor
employ
systemat
quantit
approach
evalu
inhibitori
effect
remdesivirtp
measur
effici
incorpor
monophosph
mp
amp
remdesivirmp
posit
modifi
templat
support
basepair
adenosin
analogu
posit
templat
allow
us
studi
singl
nucleotid
incorpor
ebov
rsv
enzym
complex
figur
increas
concentr
atp
remdesivirtp
increas
effici
nucleotid
incorpor
posit
data
provid
kinet
paramet
vmax
km
tabl
ratio
vmaxkm
measur
effici
amp
remdesivirmp
incorpor
ratio
vmaxkm
amp
vmaxkm
remdesivirmp
defin
select
select
valu
ebov
rdrp
rsv
rdrp
demonstr
remdesivirtp
almost
effici
use
atp
contrast
human
mitochondri
rna
polymeras
hmtrnap
discrimin
inhibitor
figur
c
high
select
valu
show
incorpor
inhibitor
ineffici
tabl
incorpor
nucleotid
analogu
inhibitor
potenti
affect
incorpor
next
nucleotid
howev
presenc
group
remdesivirtp
would
theoret
allow
nucleophil
attack
incom
nucleotid
quantifi
possibl
kinet
effect
remdesivir
subsequ
incorpor
event
termin
primer
amp
remdesivirmp
measur
rate
incorpor
natur
utp
substrat
posit
figur
ebov
rdrp
primer
util
effici
figur
contrast
result
rsv
rdrp
show
rate
ump
incorpor
reduc
primer
contain
remdesivirmp
figur
tabl
differ
primarili
driven
higher
km
valu
maximum
rate
product
format
vmax
almost
ident
satur
concentr
substrat
henc
obstacl
overcom
chain
termin
unlik
possibl
mechan
action
enzym
rsv
enzym
seem
paus
follow
incorpor
remdesivirmp
next
studi
potenti
distant
effect
incorpor
remdesivirmp
end
devis
longer
templat
allow
synthesi
fulllength
product
figur
reduc
number
incorpor
site
inhibitor
also
chang
sequenc
context
systemat
manner
adenosin
analogu
incorpor
follow
three
block
figur
control
reaction
presenc
four
natur
nucleotid
yield
expect
fulllength
product
faint
band
repres
longer
product
like
gener
templateindepend
manner
rna
synthesi
absenc
atp
presenc
remdesivirtp
termin
posit
correspond
truncat
product
result
point
delay
chain
termin
potenti
mechan
action
assess
whether
delay
chain
termin
requir
consecut
site
inhibit
devis
templat
mutat
posit
respect
case
observ
termin
rna
synthesi
posit
subtl
differ
overal
pattern
figur
henc
incorpor
remdesivirmp
posit
suffici
caus
inhibit
figur
consecut
site
inhibitor
incorpor
requir
whether
also
necessari
inhibit
could
answer
devis
templat
contain
singl
incorpor
site
posit
howev
overal
rna
product
format
decreas
prematur
termin
even
absenc
inhibitor
figur
direct
comparison
longer
product
gener
absenc
presenc
inhibitor
therefor
possibl
gener
challeng
identifi
templat
singl
uridin
give
rise
suffici
yield
fulllength
product
also
studi
whether
delay
chain
termin
posit
overcom
higher
concentr
natur
nucleotid
substrat
posit
figur
experi
concentr
mm
utp
show
enhanc
product
format
presenc
nucleotid
absenc
remdesivirtp
figur
left
panel
product
format
plateau
utp
figur
contrast
increas
product
format
seen
reaction
inhibitor
figur
right
panel
figur
henc
delay
chain
termin
overcom
higher
substrat
concentr
final
compar
inhibit
pattern
remdesivirtp
araatp
figur
aractp
previous
shown
act
chain
termin
sever
rdrp
enzym
deriv
neg
positivesens
rna
virus
compound
valid
chain
termin
hcv
rdrp
positivesens
rna
virus
previou
studi
show
signific
antivir
effect
compound
minigenom
replicon
ebov
ebov
rdrp
figur
left
panel
rsv
rdrp
figur
right
panel
yield
expect
fulllength
product
presenc
four
ntp
agreement
previou
studi
araatp
util
substrat
caus
chain
termin
enzym
contrast
util
substrat
neither
ebov
rdrp
rsv
rdrp
incorpor
inhibitor
rel
high
concentr
data
consist
previou
model
studi
point
possibl
steric
clash
modif
residu
near
activ
site
ebov
rdrp
rsv
rdrp
discuss
remdesivirmp
incorpor
posit
caus
delay
chain
termin
posit
ebov
rdrp
rsv
rdrp
overal
data
demonstr
specif
pattern
inhibit
remdesivirmp
common
polymeras
complex
remdesivir
nucleotid
analogu
prodrug
current
evalu
clinic
trial
treatment
evd
preclin
studi
shown
remdesivir
exhibit
potent
antivir
activ
multipl
ebolaviru
speci
increas
intracellular
level
ntp
pool
correl
increas
antivir
activ
suggest
correspond
triphosph
activ
form
inhibitor
viral
rdrp
target
confirm
assumpt
demonstr
remdesivirtp
substrat
purifi
ebov
rdrp
complex
remdesivirtp
adenosin
analog
therefor
compet
atp
incorpor
howev
incorpor
inhibitor
act
chain
termin
inhibit
rna
synthesi
seen
predominantli
posit
despit
subtl
sequencedepend
effect
rna
synthesi
commonli
termin
point
increas
concentr
next
nucleotid
overcom
effect
therefor
reason
conclud
delay
chain
termin
major
contributor
antivir
activ
remdesivir
broad
spectrum
antivir
activ
associ
remdesivir
rais
question
whether
delay
chain
termin
unifi
mechan
inhibit
previou
data
shown
inhibitor
also
incorpor
rsv
rdrp
inhibitor
caus
prematur
termin
fulllength
rna
product
form
similar
result
obtain
purifi
niv
rdrp
complex
consecut
site
incorpor
seem
enhanc
effect
collect
data
broad
agreement
studi
enzym
kinet
evalu
reveal
rsv
rdrp
enzym
ebov
rdrp
paus
follow
incorpor
inhibitor
despit
differ
delay
chain
termin
irrevers
therefor
domin
enzym
effici
incorpor
remdesivirmp
ebov
rsv
reduc
compar
natur
counterpart
atp
comparison
similar
experiment
approach
reveal
higher
level
discrimin
favipiravirtp
studi
purifi
influenza
polymeras
favipiravir
incorpor
opposit
templat
c
templat
u
discrimin
inhibitor
opposit
c
opposit
u
respect
high
rate
incorpor
remdesivir
like
contribut
rel
low
valu
cellbas
assay
remdesivir
inhibit
ebov
rsv
replic
cellbas
assay
valu
nm
contrast
human
rna
pol
ii
hmtrnap
seem
inhibit
presenc
remdesivirtp
measur
reduct
effici
incorpor
remdesivirmp
atp
purifi
hmtrnap
although
potenti
offtarget
effect
may
exclud
data
consist
low
cytotox
differ
cell
type
exampl
cytotox
concentr
remdesivir
gener
variou
cell
type
favipiravir
effici
use
substrat
hmtrnap
polrmt
howev
high
rate
incorpor
translat
effici
inhibit
low
inhibit
cellular
rna
polymeras
also
correl
case
valu
conclus
studi
provid
evid
show
delay
chain
termin
plausibl
mechan
action
remdesivir
ebov
delay
chain
termin
describ
earlier
context
inhibit
revers
transcriptas
rt
human
immunodefici
viru
type
hepat
b
viru
hbv
promin
exampl
mechan
action
entecavir
approv
treatment
infect
hbv
seifer
colleagu
report
hbv
polymeras
inhibit
posit
entecavir
also
shown
exhibit
antivir
activ
hiv
previou
studi
rt
reveal
major
contributor
inhibit
delay
chain
termin
posit
footprint
experi
provid
evid
show
enzym
adequ
posit
support
bind
next
nucleotid
howev
structur
reason
enzym
reposit
remain
elus
inhibitori
effect
remdesivir
even
distant
suggest
delay
chain
termin
caus
differ
mechan
unfavor
interact
incorpor
inhibitor
distinct
element
enzym
well
structur
alter
newli
synthes
rna
must
consid
regard
studi
warrant
investig
structur
ebov
rsv
niv
rdrp
complex
andor
modifi
doublestrand
rna
address
question
